# Medicare and TMS Coverage: What the LCDs Say Medicare covers transcranial magnetic stimulation (TMS) for major depressive disorder under the behavioral-health benefit, but coverage is governed by **Local Coverage Determinations (LCDs)** issued by regional **Medicare Administrative Contractors (MACs)** — not by a single National Coverage Determination.[^cms-lcd] The criteria are broadly similar across MAC jurisdictions but are not identical, and which LCD applies depends on the geography where the patient receives treatment. This article walks through what an LCD is, the typical TMS LCD criteria, how the 2026 CMS-0057-F prior-authorization rule applies to Medicare Advantage, and how traditional fee-for-service Medicare differs in practice. ## What a Local Coverage Determination actually is A **Local Coverage Determination** is a clinical-policy document issued by a Medicare Administrative Contractor — the private contractor CMS pays to administer Medicare claims in a defined geographic region. The LCD specifies the conditions under which Medicare will reimburse a given service: the qualifying diagnosis, the eligibility criteria, the contraindications, and the documentation the contractor expects to see in the medical record at audit.[^cms-lcd] There are multiple MACs across the United States, each with jurisdiction over a defined set of states. **Noridian Healthcare Solutions** administers Medicare Part B claims for California and several other western states; **Palmetto GBA** administers parts of the Southeast; **National Government Services**, **Novitas Solutions**, **CGS Administrators**, **First Coast Service Options**, and **Wisconsin Physicians Service** administer the remaining jurisdictions. Each MAC publishes its own LCD for TMS — for example, Noridian LCD L34522 and Palmetto LCD L34869 — and each LCD is a public document in the CMS Coverage Database.[^cms-lcd] LCDs are revised periodically as evidence and FDA-cleared indications evolve; the version in force at the date of service is the one the contractor adjudicates against. ## Why there is no National Coverage Determination A **National Coverage Determination (NCD)** would impose a single binding national rule on every MAC. CMS has not issued an NCD for TMS, so coverage authority defaults to the LCD framework.[^cms-lcd] The practical consequence is that the criteria a Medicare beneficiary must meet for TMS depend on where the service is rendered — California beneficiaries are adjudicated under Noridian, Southeast beneficiaries under Palmetto, and so on. The criteria are convergent because the MACs draw on the same evidentiary base — the FDA-cleared indication language for the original TMS device, the NeuroStar Advanced Therapy System under 510(k) K061053, and the Clinical TMS Society consensus recommendations — but they are not literally identical document to document.[^fda-neurostar][^perera-2016] ## The typical TMS LCD criteria The core eligibility criteria are stable across MAC LCDs. A patient's chart, at audit, is expected to document the following: - **Diagnosis** — DSM-5-TR major depressive disorder, single or recurrent episode, confirmed by a psychiatrist or qualified mental-health prescriber. - **Treatment resistance** — documented inadequate response to **two or more antidepressants** of adequate dose sustained for an adequate duration (generally ≥6 weeks at therapeutic dose) in the current episode, from at least two distinct pharmacologic classes. This criterion mirrors the FDA-cleared indication language for TMS in adults.[^fda-neurostar] - **Psychotherapy trial** — many LCDs additionally require documentation of an adequate trial of an evidence-based psychotherapy in the current episode (cognitive-behavioral therapy or interpersonal therapy are the canonical examples), or a documented clinical reason psychotherapy is not appropriate or accessible.[^cms-lcd] - **Contraindications** — no personal history of seizure or seizure disorder; no ferromagnetic implants within approximately 30 cm of the treatment coil; pregnancy considerations addressed with the treating psychiatrist. Seizure risk under contemporary safety guidelines is estimated at fewer than 1 per 60,000 sessions, but a prior seizure history remains a coverage contraindication.[^lerner-2019][^rossi-2021] - **Initial authorization** — typically covers the **acute phase of 30 to 36 sessions** plus a defined taper, consistent with the standard FDA-cleared protocol.[^perera-2016] - **Continued treatment** — additional sessions beyond the acute phase are allowed with **documented rating-scale evidence** of clinical response or partial response — most commonly serial PHQ-9 trajectories establishing measurable improvement that has not yet reached remission.[^cms-lcd] - **Maintenance TMS** — generally **not covered** under standard LCD language without separate clinical justification. Where maintenance is sought, the treating psychiatrist documents the relapse history and the clinical rationale, and the request is adjudicated separately.[^cms-lcd] Carrier-specific add-ons appear at the margins of individual LCDs — additional augmentation-trial expectations, specific psychotherapy-modality language, or particular rating-scale thresholds — but the core criteria above are common to every published TMS LCD. ## CMS-0057-F and Medicare Advantage prior authorization The **CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F)**, effective 2026, governs prior-authorization decision timeframes for a defined set of payers: Medicare Advantage organizations, state Medicaid fee-for-service and managed-care plans, CHIP fee-for-service and managed-care plans, and Qualified Health Plan issuers on the Federally-Facilitated Exchanges.[^cms-0057-f] For TMS prior-authorization requests submitted to those payers, the rule establishes: - **7 calendar days** for standard prior-authorization decisions. - **72 hours** for expedited decisions where standard timeframes would seriously jeopardize the patient's life, health, or ability to regain maximum function. CMS-0057-F **does not apply to traditional fee-for-service Medicare (Parts A and B)**, which operates under separate procedural rules. The practical effect for the TMS workflow is a substantial compression of turnaround time across the Medicare Advantage population and across Medicaid and exchange plans — the prior-authorization step that historically ran 10 to 15 business days for many of these payers is now bounded at 7 calendar days standard.[^cms-0057-f] ## Medicare Advantage vs. traditional fee-for-service Medicare The two principal Medicare delivery models handle TMS differently at the administrative layer. **Medicare Advantage (Part C) plans** are administered by private payers under contract with CMS. Prior authorization for TMS is required by virtually every Medicare Advantage plan, and the CMS-0057-F timeframes apply.[^cms-0057-f] The plan's medical policy is required to be at least as generous as the underlying MAC LCD, but the plan may apply its own utilization-management overlay — additional documentation expectations, specific session-count language, or particular rating-scale requirements — within the LCD floor. **Traditional fee-for-service Medicare (Parts A and B)** generally does not require prior authorization for the outpatient TMS CPT codes. Instead, the **MAC adjudicates the claim against the LCD after the service is rendered**, and the treating clinic screens patients against the applicable LCD criteria before initiating treatment.[^cms-lcd] The patient's pre-treatment experience differs — there is typically no written approval letter — but the clinic's documentation requirements are functionally similar. The chart at the time of audit must reflect the same LCD criteria a Medicare Advantage prior-authorization reviewer would have required up front. The [prior-authorization process](/blog/prior-authorization-process-for-tms/) walkthrough covers the documentation packet, the peer-to-peer review, and the appeals path in more detail for the population to which prior authorization applies. ## Medicaid State **Medicaid programs** cover TMS for major depressive disorder under criteria that vary meaningfully from state to state, because Medicaid is jointly administered by CMS and the individual states. California's **Medi-Cal** program covers TMS for MDD with prior authorization under criteria that closely track the Noridian LCD framework — diagnosis, two failed adequate antidepressant trials, psychotherapy documentation, and contraindication screening.[^cms-lcd] Other states' Medicaid programs apply their own coverage policies, and CMS-0057-F's 7-day standard / 72-hour expedited timeframes apply to Medicaid prior-authorization decisions under the rule.[^cms-0057-f] Specific state-by-state Medicaid coverage details are best confirmed at the time of insurance verification rather than assumed. ## What the patient needs to know The patient's contribution to the Medicare TMS verification process is narrower than the clinic's, but it is consequential. Three pieces of information determine which framework applies: - **Whether the plan is traditional fee-for-service Medicare or Medicare Advantage.** The plan card usually identifies this directly — a card from the Centers for Medicare & Medicaid Services indicates traditional Medicare, while a card from a private insurer with "Medicare Advantage" or "Part C" branding indicates an Advantage plan. - **The geographic region** where treatment will be rendered — which determines the MAC and therefore the controlling LCD. For Anaheim and Orange County patients, the applicable MAC is Noridian.[^cms-lcd] - **Accurate prior-treatment history** — the antidepressant medications tried in the current episode, the doses and durations, the psychotherapy course if any, and the prescribing or treating clinicians. This is the record the LCD criteria are evaluated against, and incomplete prior-treatment history is the most common documentation gap. ## What this article does not promise This article is educational. It is **not** a guarantee of coverage for any individual patient — coverage determinations are made by the MAC or the Medicare Advantage plan against the patient's specific clinical record, not against general criteria. It is **not** a substitute for the clinic's [insurance verification process](/insurance/verify/), which confirms benefits, the controlling LCD, the applicable prior-authorization requirement, and any plan-specific utilization-management overlay before treatment begins. And it is **not** an assertion about specific plan features — Medicare Advantage plan medical policies vary even within a single payer, and the controlling document is always the medical policy in force at the date of service. ## Key takeaways - **Medicare covers TMS for major depressive disorder**, but coverage is governed by **Local Coverage Determinations** issued by regional Medicare Administrative Contractors — **not** by a single National Coverage Determination. - The **typical LCD criteria** are a DSM-5-TR MDD diagnosis, failure of **two or more adequate antidepressant trials** (therapeutic dose × ≥6 weeks) in the current episode, often a documented psychotherapy trial, and absence of seizure history and ferromagnetic-implant contraindications. - Initial LCD authorization typically covers the **30 to 36 session acute phase** plus a defined taper; continued treatment requires documented rating-scale response; **maintenance TMS is generally not covered** without separate justification. - **CMS-0057-F (2026)** establishes **7-day standard and 72-hour expedited** prior-authorization decision timeframes for Medicare Advantage, Medicaid, CHIP, and Federally-Facilitated Exchange QHPs — but does **not** apply to traditional fee-for-service Medicare. - **Medicare Advantage** requires prior authorization for TMS; **traditional fee-for-service Medicare** generally does not, with the MAC adjudicating the claim against the LCD after service. - The patient's role is providing the plan card, accurate prior-treatment history, and authorization to verify benefits; the clinic identifies the controlling LCD and prepares the record. For patients in Anaheim, Orange County, and the broader 30-mile radius, the controlling MAC is Noridian, and the clinic's insurance team identifies the applicable LCD, confirms the plan type, and prepares the documentation the LCD requires. The standard starting point is the [insurance verification form](/insurance/verify/); the [TMS therapy](/services/tms-therapy/) page describes the clinical service the coverage is being verified for; and the [prior-authorization process](/blog/prior-authorization-process-for-tms/) walkthrough covers what happens next for patients on Medicare Advantage and commercial plans. ## Sources / Further reading [^cms-lcd]: Centers for Medicare & Medicaid Services. *Medicare Coverage Database*, Local Coverage Determinations for Transcranial Magnetic Stimulation (e.g., Noridian LCD L34522; Palmetto LCD L34869). There is no National Coverage Determination (NCD) for TMS; coverage is governed by Local Coverage Determinations issued by Medicare Administrative Contractors. LCD criteria, contraindications, and continued-treatment language are public and revised periodically; the version in force at the date of service controls. [^cms-0057-f]: Centers for Medicare & Medicaid Services. Final Rule CMS-0057-F, *Advancing Interoperability and Improving Prior Authorization Processes*, effective 2026 — establishing 7-day standard and 72-hour expedited prior-authorization decision timeframes for Medicare Advantage organizations, state Medicaid fee-for-service and managed-care plans, CHIP fee-for-service and managed-care plans, and Qualified Health Plan issuers on the Federally-Facilitated Exchanges. The rule does not apply to traditional fee-for-service Medicare. [^fda-neurostar]: U.S. Food and Drug Administration. 510(k) Premarket Notification K061053, NeuroStar TMS Therapy System (Neuronetics, Inc.), cleared 2008 for treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication. The FDA-cleared indication language is the basis for most LCD and payer-policy "failure of 2+ antidepressant trials" criteria. [^perera-2016]: Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A, Wirecki TS. The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder. *Brain Stimulation*. 2016;9(3):336–346. [^lerner-2019]: Lerner AJ, Wassermann EM, Tamir DI. Seizures from transcranial magnetic stimulation 2012–2016: results of a survey of active laboratories and clinics. *Clinical Neurophysiology*. 2019;130(8):1409–1416. [^rossi-2021]: Rossi S, Antal A, Bestmann S, et al. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues. *Clinical Neurophysiology*. 2021;132(1):269–306.